Tricision Patient guide
Patient guide

Dendritic-cell and mRNA vaccines for glioblastoma: how they work and what is proven

A therapeutic cancer vaccine does not prevent glioblastoma; it tries to teach the immune system to attack tumor cells left after surgery and radiotherapy. The main types differ in what they show the immune system: tumor lysate (everything in the tumor), fixed peptides (a few shared antigens), or mRNA encoding antigens chosen from the patient's own tumor. Trials show vaccines are safe and often produce immune responses; proof that they lengthen survival is still limited to one large externally controlled trial and several smaller studies, so every vaccine today is investigational or offered under special frameworks.

Medically reviewed by Prof. Youwen He, MD, PhD · Last updated 16 October 2026

From your tumor to your vaccine
  1. 1Your tumor is sequencedWhole-exome and RNA sequencing of the tissue from surgery reads every mutation.
  2. 2Targets are chosenFrom hundreds of changes, the antigens most likely to be recognized by your immune system are selected.
  3. 3mRNA is madeThe chosen targets are encoded as mRNA with triVac modification.
  4. 4Your dendritic cells are loadedCells from your own blood take up the mRNA and display the antigens on their surface.
  5. 5T cells find the tumorReturned as three doses, the cells train T cells that seek out residual tumor; anti-PD-1 keeps them active.

Schematic. Animation pauses if your device is set to reduce motion.

Why the immune system needs help against glioblastoma

Glioblastoma hides well. The brain limits immune traffic, the tumor secretes molecules that switch off T cells, and steroids and chemotherapy lower immune counts further. Checkpoint inhibitors that work in melanoma have failed in glioblastoma trials, largely because there are too few tumor-specific T cells to release. A vaccine tries to create those T cells by presenting tumor antigens together with a danger signal, so that the immune system recognizes the tumor as foreign.

Dendritic cells: the instructors

Dendritic cells are the immune system's teachers: they take up antigen, travel to lymph nodes and show it to T cells. In a dendritic-cell vaccine, monocytes are collected from the patient's blood by leukapheresis, matured into dendritic cells in a laboratory, loaded with tumor antigens and injected back, usually into the skin near lymph nodes, in a course of several doses. The loading step is where products differ.

How a dendritic cell teaches a T cell
  1. 1Antigen presentedThe dendritic cell displays pieces of the chosen antigens on its surface, held in MHC molecules.
  2. 2Receptor matchA T cell whose receptor fits that antigen locks on; co-stimulation signals confirm the match.
  3. 3Activation and expansionThe T cell switches on and divides into a clone of identical cells that all hunt the same target.

Schematic. This happens in lymph nodes near the injection site over days.

How a dendritic-cell vaccine is made and given
  1. 1
    Blood collection

    Monocytes are collected by leukapheresis, a few hours like a blood donation

  2. 2
    Maturation

    In a GMP laboratory the monocytes become dendritic cells over several days

  3. 3
    Loading

    The cells are loaded with tumor antigen: lysate, peptides or sequenced mRNA

  4. 4
    Injection

    Given into the skin near lymph nodes, as a course of several doses

  5. 5
    Immune response

    Dendritic cells teach T cells, which travel to the tumor; combination drugs keep them active

What the vaccine shows the immune system

  • Tumor lysate: the patient's tumor tissue is broken up and the whole mixture is loaded. It contains every protein in the sample, most of them normal, and needs fresh frozen tissue from surgery. DCVax-L and most German clinic vaccines work this way.
  • Fixed peptides: short pieces of proteins that many glioblastomas share, such as survivin or EGFRvIII. Off-the-shelf and cheap, but the tumor can escape by losing the one target; the EGFRvIII vaccine rindopepimut failed its Phase 3 for this reason.
  • mRNA encoding selected antigens: the tumor is sequenced, targets including patient-specific mutations (neoantigens) are chosen, and mRNA for them is made and loaded into dendritic cells, or packaged in lipid nanoparticles (LNP) and injected directly. This is the approach used in our program and in the personalized mRNA vaccines being tested in melanoma.
Two ways to deliver the same mRNA design
  1. 1Cell routeYour dendritic cells are collected, loaded with the mRNA in the laboratory and returned as three doses. Recommended; this is where the clinical data are.
  2. 2In-body routeThe Survivin mRNA is packaged in lipid nanoparticles and injected directly; your own dendritic cells take it up inside the body. About one-tenth of the cost; less efficacy evidence.

The multidisciplinary team recommends one route in writing for each patient.

Tumor lysateFixed peptidesSequenced mRNA
What the immune system seesEverything in the tumor sample, mostly normal proteinsA few antigens shared by many tumorsAntigens chosen from your tumor, including neoantigens
Tissue neededFresh frozen tumor tissue from surgeryNoneSmall amount; often archived pathology samples
ExamplesDCVax-L, German clinic vaccinesRindopepimut (failed Phase 3), survivin peptidesTricision mRNA-DC; personalized mRNA in melanoma
Main weaknessUndefined targets; needs banked tissueTumor escapes by losing the one targetNewer; smaller patient numbers so far

What has been shown

  • Safety: across hundreds of patients in trials and programs, dendritic-cell vaccines cause injection-site reactions, fatigue and flu-like symptoms; serious toxicity is rare.
  • Immune responses: most studies find vaccine-specific T cells in blood after vaccination. This shows the vaccine did what it was designed to do, not that the tumor was controlled.
  • Survival: the largest study, the DCVax-L Phase 3 (331 patients), reported median survival of 19.3 months versus 16.5 in external controls. A randomized Phase 2 of another lysate vaccine (Audencel) found no benefit. Smaller single-arm series, including ours, report longer time to recurrence than historical benchmarks but have no concurrent control. No vaccine is approved for glioblastoma anywhere as of October 2026.

What combination therapy adds

Because the tumor suppresses the T cells a vaccine creates, most modern protocols add something: a checkpoint inhibitor such as anti-PD-1 to keep T cells active, poly I:C or similar adjuvants as danger signals, low-dose cyclophosphamide to reduce regulatory T cells, or oncolytic virus. Whether any of these combinations beats vaccine alone has not been settled in a randomized trial. Our program uses the vaccine with anti-PD-1, poly I:C and low-dose cyclophosphamide, and reports its results with that caveat.

How checkpoint blockade helps the vaccine work
  1. 1T cell held backTumor cells display PD-L1, a "stop" signal that switches off T cells that reach them.
  2. 2Anti-PD-1 antibodyThe antibody binds the receptor on the T cell so the stop signal is no longer received.
  3. 3T cells attackVaccine-trained T cells can now recognize and kill tumor cells that display their target.

Schematic. Checkpoint inhibitors alone have not worked in glioblastoma trials; the vaccine supplies the tumor-specific T cells they need.

Questions to ask about any vaccine

  1. What does it load: lysate, peptides, or sequenced mRNA? Does it need frozen tissue?
  2. How many doses, over what period, and where does each have to be given?
  3. What combination drugs are included, and who monitors their side effects?
  4. What are the published results, with patient numbers, endpoint and comparison group?
  5. Under what regulatory basis is it given: trial, authorized program, or individual treatment attempt?

Our own answers are on the delivery options and evidence sections, and a side-by-side view of the main routes is on the comparison page.

Questions families ask

Can a vaccine replace radiotherapy or temozolomide?

No. Every credible program gives the vaccine in addition to standard treatment. A provider who suggests skipping standard care should be avoided.

Does the vaccine work if I am on steroids?

High-dose dexamethasone suppresses the immune response. Most programs require the steroid dose to be low and stable before the first vaccine dose, and manage swelling in other ways where possible.

How long does it take to make a personalized vaccine?

Typically four to eight weeks from tissue and blood collection, which is why manufacturing is scheduled during radiotherapy so that the first dose can follow soon after it.

Related guides

Sources

  1. Liau LM, et al. DCVax-L Phase 3 externally controlled cohort trial. JAMA Oncology 2023 doi.org
  2. Buchroithner J, et al. Audencel Phase II randomized trial. Cancers 2018 doi.org
  3. Weller M, et al. Rindopepimut with temozolomide for newly diagnosed EGFRvIII-expressing glioblastoma (ACT IV). Lancet Oncology 2017 doi.org
  4. Zhu, et al. Combination immunotherapy of glioblastoma with dendritic cell cancer vaccines, anti-PD-1 and poly I:C. J Pharm Anal 2023 doi.org

Considering treatment in China?

Send the patient's records for a remote review. A coordinator confirms receipt within one business day; the multidisciplinary team's report and a written estimate follow in about a week, before any decision or payment.

Request a records reviewAbout the program